Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Clive S Zent; Timothy G Call; Deborah A Bowen; Michael J Conte; Betsy R LaPlant; Thomas E Witzig; Stephen M Ansell; George J Weiner

doi:10.3109/10428194.2015.1016932

Back

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Journal article

Peer reviewed

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Clive S Zent, Timothy G Call, Deborah A Bowen, Michael J Conte, Betsy R LaPlant, Thomas E Witzig, Stephen M Ansell and George J Weiner

Leukemia & lymphoma, Vol.56(8), pp.2373-2378

08/03/2015

DOI: 10.3109/10428194.2015.1016932

PMID: 25676035

Files and links (1)

url

http://doi.org/10.3109/10428194.2015.1016932View

Open Access

Abstract

Poly-[1-6]-β-glucopyranosyl-[1-3]-β-glucopyranose (PGG) beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential. This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days. PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study. There were three grade 3-4 toxicities at least possibly attributed to treatment. Nineteen (95%) patients responded to treatment with 13 (65%) complete responses. All patients were alive at a median follow-up of 24.4 months (range: 9.5-37). Eleven patients had progressive disease (median 17.6 months, 95% confidence interval [CI]: 9.7, 32.1) and eight patients were retreated (median 35.3 months, 95% CI: 17.9, not reached). We conclude that PGG beta glucan, alemtuzumab and rituximab treatment is tolerable and results in a high complete response rate.

CLL

Chronic lymphocytic leukemia/small lymphocytic lymphoma

alemtuzumab

PGG beta glucan

rituximab

high risk

Details

Title: Subtitle: Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates
Creators: Clive S Zent - Division of Hematology
Timothy G Call - Division of Hematology
Deborah A Bowen - Division of Hematology
Michael J Conte - Division of Hematology
Betsy R LaPlant - Department of Health Sciences Research, Mayo Clinic
Thomas E Witzig - Division of Hematology
Stephen M Ansell - Division of Hematology
George J Weiner - Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa
Resource Type: Journal article
Publication Details: Leukemia & lymphoma, Vol.56(8), pp.2373-2378
DOI: 10.3109/10428194.2015.1016932
PMID: 25676035
NLM abbreviation: Leuk Lymphoma
ISSN: 1042-8194
eISSN: 1029-2403
Publisher: Taylor & Francis
Language: English
Date published: 08/03/2015
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
Record Identifier: 9984094545302771

Metrics

20 Record Views

26 Times Cited - Web of Science